sign up for retatrutide trial Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the retatrutide phase 3 trial dosage
Pay in 4 interest-free payments of $6.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22













30074-7/asset/5367a357-b6ae-4d9a-9e38-d2422800e400/main.assets/gr3_lrg.jpg)





30194-9/asset/e2a34f3b-6f8a-425f-9e34-2cf394cbb616/main.assets/gr4_lrg.jpg)

00459-9/asset/e4c0896a-ac7a-460c-8a8f-e5b97bab8187/main.assets/gr2_lrg.jpg)





